Hikal Ltd
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad {Maharashtra). The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal's R & D facilities are located in Pune.[1]
- Market Cap ₹ 3,058 Cr.
- Current Price ₹ 248
- High / Low ₹ 465 / 245
- Stock P/E 48.6
- Book Value ₹ 102
- Dividend Yield 0.56 %
- ROCE 9.85 %
- ROE 7.39 %
- Face Value ₹ 2.00
Pros
- Company has been maintaining a healthy dividend payout of 17.0%
Cons
- The company has delivered a poor sales growth of 4.29% over past five years.
- Company has a low return on equity of 6.81% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
829 | 872 | 926 | 1,014 | 1,296 | 1,590 | 1,507 | 1,720 | 1,943 | 2,023 | 1,785 | 1,860 | 1,833 | |
642 | 689 | 745 | 814 | 1,054 | 1,291 | 1,234 | 1,398 | 1,602 | 1,765 | 1,518 | 1,531 | 1,538 | |
Operating Profit | 187 | 182 | 181 | 200 | 242 | 298 | 273 | 323 | 341 | 258 | 267 | 328 | 295 |
OPM % | 23% | 21% | 20% | 20% | 19% | 19% | 18% | 19% | 18% | 13% | 15% | 18% | 16% |
34 | 2 | 2 | 1 | 4 | 2 | -12 | 5 | 5 | 5 | 2 | 5 | 6 | |
Interest | 68 | 60 | 62 | 48 | 49 | 58 | 52 | 36 | 31 | 48 | 56 | 75 | 72 |
Depreciation | 55 | 64 | 67 | 69 | 86 | 93 | 82 | 85 | 96 | 109 | 118 | 134 | 142 |
Profit before tax | 98 | 60 | 53 | 83 | 112 | 149 | 127 | 206 | 219 | 105 | 95 | 124 | 86 |
Tax % | 35% | 32% | 22% | 15% | 31% | 31% | 33% | 36% | 27% | 26% | 27% | 27% | |
64 | 41 | 41 | 71 | 77 | 103 | 84 | 133 | 161 | 78 | 70 | 91 | 63 | |
EPS in Rs | 5.19 | 3.29 | 3.35 | 5.73 | 6.26 | 8.36 | 6.85 | 10.80 | 13.02 | 6.36 | 5.64 | 7.37 | 5.11 |
Dividend Payout % | 12% | 20% | 20% | 14% | 13% | 14% | 18% | 19% | 12% | 19% | 21% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 4% |
3 Years: | -1% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | -1% |
3 Years: | -17% |
TTM: | -7% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 7% |
3 Years: | -9% |
1 Year: | -27% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 10% |
3 Years: | 7% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16 | 16 | 16 | 16 | 16 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
Reserves | 489 | 517 | 548 | 589 | 653 | 732 | 792 | 909 | 1,043 | 1,109 | 1,163 | 1,238 |
546 | 547 | 505 | 598 | 635 | 661 | 646 | 610 | 675 | 748 | 818 | 765 | |
219 | 212 | 206 | 177 | 237 | 268 | 306 | 370 | 470 | 504 | 482 | 502 | |
Total Liabilities | 1,271 | 1,293 | 1,276 | 1,379 | 1,542 | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 |
644 | 639 | 623 | 668 | 634 | 713 | 735 | 713 | 879 | 948 | 1,071 | 1,364 | |
CWIP | 61 | 62 | 66 | 63 | 118 | 79 | 161 | 254 | 295 | 412 | 414 | 121 |
Investments | 3 | 3 | 3 | 4 | 3 | 1 | 1 | 1 | 11 | 5 | 5 | 10 |
562 | 589 | 584 | 645 | 788 | 893 | 871 | 946 | 1,028 | 1,020 | 997 | 1,034 | |
Total Assets | 1,271 | 1,293 | 1,276 | 1,379 | 1,542 | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
155 | 102 | 186 | 163 | 139 | 186 | 285 | 229 | 294 | 315 | 187 | 280 | |
-23 | -43 | -64 | -103 | -110 | -125 | -164 | -156 | -284 | -292 | -174 | -136 | |
-124 | -69 | -124 | -63 | -25 | -55 | -101 | -97 | -6 | -8 | -27 | -144 | |
Net Cash Flow | 7 | -10 | -2 | -2 | 4 | 6 | 20 | -24 | 4 | 15 | -14 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 39 | 54 | 44 | 92 | 81 | 80 | 82 | 103 | 82 | 80 | 113 | 103 |
Inventory Days | 302 | 268 | 229 | 189 | 158 | 156 | 147 | 107 | 121 | 104 | 134 | 146 |
Days Payable | 127 | 117 | 101 | 93 | 86 | 68 | 95 | 92 | 91 | 103 | 123 | 133 |
Cash Conversion Cycle | 214 | 205 | 173 | 188 | 153 | 168 | 135 | 118 | 112 | 81 | 124 | 116 |
Working Capital Days | 0 | -13 | 29 | 43 | 29 | 45 | 28 | 39 | 26 | 39 | 39 | 37 |
ROCE % | 16% | 11% | 11% | 12% | 13% | 15% | 14% | 16% | 15% | 8% | 8% | 10% |
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 2d
-
Disclosure Under Regulation 30 Of SEBI Listing Regulations
7 Oct - CRISIL assigned “Crisil ESG 55” to Hikal, based on public-domain data (disclosed Oct 7, 2025).
-
Newspaper Advertisement Regarding Saksham Niveshak For Updating KYC And Re-Lodgment Of Transfer Requests Of Physical Shares
7 Oct - Published Oct 07, 2025 ad for ‘Saksham Niveshak’ KYC campaign and special physical share re-lodgement window.
-
Change Of Email Address Of The Registrar And Share Transfer Agent (''RTA'') Of The Company
1 Oct - MIIPL RTA introduced new generic investor email investor.helpdesk@in.mpms.mufg.com effective 1 Oct 2025.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
1 Oct - Mr Berjis Desai resigned as Non-Executive Independent Director effective Oct 01, 2025; cited preoccupation.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Sep 2025TranscriptNotesPPT
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024TranscriptPPT
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021Transcript PPT
-
Aug 2020Transcript PPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptNotesPPT
-
Mar 2019TranscriptNotesPPT
-
Nov 2018Transcript PPT
-
May 2018TranscriptPPT
-
Mar 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
Business Segments
1. Pharmaceuticals [1]: Active pharmaceutical ingredients (APIs), intermediates and advanced intermediates.
2. CDMO: ** Company has a pipeline of 13-14 products in various development stages, with 2 expected to be launched by FY26. The company focuses on NCEs and advanced intermediates, attracting growing interest from innovator companies.[2][3]
3. Crop Protection: Active ingredients, advanced intermediates, intermediates. Custom Synthesis and Contract Manufacturing of Agrochemicals, Intermediates and Specialty Chemicals. (Personal care products, Battery chemicals, and home care)
4. Research & Technology: Process development, new product development, contract and custom development. It caters to the following Industries: Pharmaceutical (Generics & Custom Manufacturing), Biotech, Animal Healthcare, Crop Protection, Specialty Chemicals and Biocides, and Food. [4] [5]